Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06420349 | NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma | terminated | Phase 1 | 7 | Mayo ClinicOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT05336409 | A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies(ELiPSE-1) | terminated | Phase 1 | 28 | Century Therapeutics, Inc.INDUSTRY | 1 | Dec 18, 2025 | clinicaltrials |
| NCT05860296 | Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers | terminated | Phase 1 / Phase 2 | 36 | SignalChem Lifesciences CorporationINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT04688658 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 13 | John KirkwoodOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05313009 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | terminated | Phase 1 / Phase 2 | 5 | Medical University of South CarolinaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05652868 | Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer | terminated | Phase 1 | 227 | Mythic TherapeuticsINDUSTRY | 7 | Dec 16, 2025 | clinicaltrials |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03698552 | ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06438783 | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors | terminated | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT06851442 | Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 8 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 12, 2025 | clinicaltrials |
| NCT03260504 | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | terminated | Phase 1 | 6 | University of WashingtonOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT06199466 | A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05127174 | Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms | terminated | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05393713 | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study | terminated | Phase 1 | 3 | Mayo ClinicOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05427396 | A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05083208 | PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma | terminated | Phase 1 | 12 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05918055 | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06295549 | Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 11 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | terminated | Phase 1 | 50 | Blueprint Medicines CorporationINDUSTRY | 3 | Nov 28, 2025 | clinicaltrials |
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer(AMEERA-1) | terminated | Phase 1 / Phase 2 | 136 | SanofiINDUSTRY | 10 | Nov 24, 2025 | clinicaltrials |
| NCT06304636 | Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma(DC15-MM-01) | terminated | Phase 1 | 4 | Cartesian TherapeuticsINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02706353 | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 31 | TransgeneINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT06320080 | Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma. | terminated | Phase 1 | 22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | terminated | Phase 1 | 4 | Colin D. Weekes, M.D., PhDOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05364944 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)(OXTEND-01) | terminated | Phase 1 | 19 | Debiopharm International SAINDUSTRY | 8 | Nov 17, 2025 | clinicaltrials |
| NCT05525286 | Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma(CLAUDIO-01) | terminated | Phase 1 / Phase 2 | 31 | SOTIO Biotech a.s.INDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies | terminated | Phase 1 | 17 | Bolt Biotherapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | terminated | Phase 1 | 154 | Novartis PharmaceuticalsINDUSTRY | 9 | Nov 14, 2025 | clinicaltrials |
| NCT04106492 | Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 53 | Shasqi, Inc.INDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2025 | clinicaltrials |
| NCT05037500 | Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05065047 | Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma | terminated | Phase 1 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 120 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Nov 12, 2025 | clinicaltrials |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | terminated | Phase 1 | 25 | Kahr MedicalINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors | terminated | Phase 1 / Phase 2 | 8 | Alaunos TherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05617040 | Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer | terminated | Phase 1 / Phase 2 | 22 | Barinthus BiotherapeuticsINDUSTRY | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 82 | Nuvation Bio Inc.INDUSTRY | 2 | Nov 6, 2025 | clinicaltrials |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies(UPCC 25406) | terminated | Phase 1 / Phase 2 | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 15 | Incyte CorporationINDUSTRY | 3 | Nov 4, 2025 | clinicaltrials |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | terminated | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04982224 | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer | terminated | Phase 1 | 30 | Regeneron PharmaceuticalsINDUSTRY | 1 | Nov 3, 2025 | clinicaltrials |
| NCT06069778 | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 1 | BioNTech SEINDUSTRY | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT05469178 | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | terminated | Phase 1 / Phase 2 | 26 | BerGenBio ASAINDUSTRY | 7 | Oct 29, 2025 | clinicaltrials |
| NCT06248086 | A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas | terminated | Phase 1 | 1 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Oct 28, 2025 | clinicaltrials |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | terminated | Phase 1 / Phase 2 | 93 | CRISPR Therapeutics AGINDUSTRY | 6 | Oct 24, 2025 | clinicaltrials |
| NCT04543188 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | terminated | Phase 1 | 65 | PfizerINDUSTRY | 3 | Oct 23, 2025 | clinicaltrials |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | terminated | Phase 1 / Phase 2 | 23 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 22, 2025source: clinicaltrials